Recent News

• 02.09.2026 - Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
• 02.03.2026 - Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
• 02.02.2026 - Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care
• 01.22.2026 - S-3 - Registration statement under Securities Act of 1933
• 01.22.2026 - 8-K - Current report
• 01.22.2026 - 4/A - Statement of changes in beneficial ownership of securities
• 01.21.2026 - SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
• 01.20.2026 - 8-K - Current report
• 01.14.2026 - Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico
• 12.15.2025 - 4 - Statement of changes in beneficial ownership of securities

Recent Filings

• 01.22.2026 - S-3 Registration statement under Securities Act of 1933
• 01.22.2026 - 8-K Current report
• 01.22.2026 - 4/A Statement of changes in beneficial ownership of securities
• 01.21.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.20.2026 - EX-99.1 EX-99.1
• 01.20.2026 - 8-K Current report